IMPULSE: the impact of gender on the presentation and management of aortic stenosis across Europe.

In the recent PARTNER 3 trial, 10 which compared surgery with SAVR in low-risk patients, subgroup analyses of the primary endpoint at 1 year showed no heterogeneity of treatment effect by gender (p=0.27), but for women the endpoint rate for SAVR was 18.5% (men 13.8%) and 8.1% for TAVI (men 8.7%), showing a clear trend for an increased benefit of women undergoing TAVI instead of SAVR (rate difference −10.4%; 95% CI −18.3% to −2.5%).

also in 19,460 other papers